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Abstract Conjugated linoleic acids (CLA) have recently been
recognized to reduce body fat and plasma lipids in some ani-
mals. This study demonstrated that the steatosis accompanying
the fat loss induced by trans-10,cis-12-C18:2 (CLA2) and not cis-
9,trans-11-C18:2 (CLA1) isomer in C57BL/6j mice was not due
to an alteration of the liver lipoprotein production that was even
increased. The 3-fold decrease in plasma triacylglycerol con-
tents and the induction of mRNA expression of low-density
lipoprotein receptors concomitantly observed in CLA2-fed
mice suggested an increase in the lipoprotein clearance at the
level of the liver itself. CLA1 feeding produced similar but at-
tenuated e¡ects on triglyceridaemia only.
1 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
During the last years, considerable attention has been fo-
cused on conjugated linoleic acids (CLA), a group of dienoic
isomers of linoleic acid, that have been shown to exhibit
unique properties such as anti-carcinogenic [1,2], anti-athero-
genic [3] and body fat reducing [4,5] e¡ects in animal models.
Two CLA isomers, cis-9,trans-11-C18:2 (CLA1) that has been
found in ruminant meat and dietary products, and trans-
10,cis-12-C18:2 (CLA2), were used in approximately equal
amounts in commercial mixtures administered for most of
the physiological studies (for a review see [6]). More recently
with the use of puri¢ed CLA isomers, evidence has accumu-
lated that CLA2 was the isomer actually altering body fat
mass [7], while both CLA1 and CLA2 were found to be re-
sponsible for cancer prevention [8,9]. However, in addition to
the reduction of the total body fat mass reported with CLA
mixtures in rats, chickens [10] and mice [4] and with CLA2 in
mice [5] and even men [11], a dramatic enlargement of liver
with steatosis was shown to develop during CLA2 feeding
[12,13].
The reduction of body fat mass by CLA mixtures has been
associated with a decreased activity of lipoprotein lipase
(LPL) of adipose tissues and with an increased activity of
total carnitine palmitoyltransferase in periepididymal adipose
and muscle tissues [4]. Adipocyte apoptosis has also been
evoked [12].
Liver steatosis is often associated with obesity, diabetes,
hyperinsulinemia and very low-density lipoprotein (VLDL)
overproduction [14]. The hyperinsulinaemia met in CLA2-
fed mice [13] would cause the greater level of gene expression
of liver enzymes related to fatty acid (FA) uptake and to
lipogenesis, which would explain, at least in part, the setup
of the steatosis, as it has been shown in the hyperinsulinaemic
fa/fa Zucker rats [15]. Besides, an alteration of VLDL secre-
tion rates could also result in liver fat accumulation as de-
scribed in suncus [16]. However, little is known about the
e¡ects of CLA on liver lipoprotein secretion. Recent studies
indicate that CLA2 reduced both apoB synthesis and triacyl-
glycerol (TAG) secretion in HepG2 cells [17,18], but the po-
tential lipid-lowering e¡ects of CLA in various species remain
confused since decreases or increases in plasma TAG levels in
rabbits, rats and hamsters have been observed [19^22].
Owing to the pivotal role of the liver in the lipid partition-
ing, the aim of the study was to investigate, in C57BL/6j mice,
the individual e¡ects of the main two puri¢ed CLA isomers
on body and lipid parameters, on the capacity of the liver to
secrete VLDL, on activity and mRNA expression of proteins
involved in VLDL clearance and FA esteri¢cation.
2. Materials and methods
2.1. Animals and treatment
7 weeks old C57BL/6j male mice (Harlan, Gannat, France) were
housed by pools of four animals in plastic cages. After 1 week of
adaptation to the control diet (see below), they were randomly allo-
cated to a basal diet containing, in g per kg: casein, 180; corn starch,
460; sucrose, 220; cellulose, 20; mineral mixture, 50; vitamin mixture,
10; sun£ower oil, 49; linseed oil, 1 (for the detailed composition of
mineral and vitamin mixtures, see [23]). The three experimental diets
(n=16 for each) were obtained by enrichment with 10 g of either of
the following FA esteri¢ed as TAG: C18:1 n9 (oleic acid; control se-
ries), cis-9,trans-11-C18:2 (CLA1 series) or trans-10,cis-12-C18:2 (CLA2
series). After 4 weeks the animals used in the fed state were anesthe-
tized with iso£urane and divided into series of eight mice for each
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diet. The ¢rst series was intended to plasma analysis, then to the
determination of VLDL-apoB secretion; the second series was de-
voted to sampling of liver and periepididymal adipose tissue that
were quickly blotted with absorbent paper and frozen in liquid nitro-
gen for further analysis.
2.2. Lipid analysis
Total liver lipids were extracted according to Folch [24] and deter-
mined by gravimetry, then TAG contents were quanti¢ed by the thin-
layer chromatography-£ame ionization detector (TLC-FID) method
[25]. Plasma TAG concentrations were determined using a commercial
kit (Sigma-Diagnostics, Saint-Quentin-Fallavier, France).
2.3. Determination of VLDL-apoB secretion by the liver
Shortly after anesthesia, about 0.3 ml of blood was collected from
the tail vein as the control sample. Animals were then injected via a
jugular vein with 100 Wl of 10% Triton WR-1339 in saline solution to
block VLDL degradation [26] and blood samplings were performed
every 30 min over 90 min. Serum samples were obtained from blood
after a clotting time of 30 min at room temperature and a centrifu-
gation of 5 min at 6500Ug. ApoB concentrations were determined
using a diagnostic kit from Sigma. The control sample (collected
before Triton WR-1339 injection) was also used for TAG and apoB
basal level measurements.
2.4. Determination of heart and liver lipolytic activities
The protocol used was that of Iverius and Ostlund-Lindquist [27].
Heart and liver samples were homogenized in a cold bu¡er (1/10, w/v)
containing 0.25 M sucrose, 10 mM Tris^HCl (pH 7.4), 1 mM ethyl-
enediamine tetraacetic acid (EDTA), 12 mM deoxycholate and 10 im-
munizing units (IU)/ml heparin. The supernatants obtained after cen-
trifugation at 12 000Ug for 20 min at 4‡C were half diluted with the
same bu¡er deprived of deoxycholate and heparin. Lipolytic activities
determined on tissue homogenates corresponded to amounts of
[3H]oleic acid released from radiolabeled triolein in the following pro-
cedure: a sample of 100 Wl of homogenate supernatant was added to
mixtures containing 0.1, 0.5, 1 or 2 mM triolein emulsi¢ed with
tri(9,10[3H]oleoyl)glycerol (Perkin Elmer, Life Sciences Inc., Boston,
MA, USA) (0.22 WCi/assay), 5% gum arabic, 0.2 M Tris^HCl (pH
8.6), 10% heat-inactivated chicken serum as the LPL activator and
1 or 0.1 M NaCl (see below), in a ¢nal volume of 200 Wl. The in-
cubation was carried out at 37‡C for 1 h and the amount of [3H]oleate
released through lipase action was measured by scintillation counting
after liquid^liquid extraction [28]. Hepatic and cardiac LPL activities
were calculated by subtracting total lipase activity performed in 0.1 M
NaCl media from LPL non-speci¢c lipolytic activity performed in 1 M
NaCl media [29]. LPL activity was expressed as nmol of oleate re-
leased per h per mg of supernatant protein. As the hepatic LPL
activity was practically undetectable, lipolytic activities were attrib-
uted to hepatic lipase (HL). The protein concentration was deter-
mined through the bicinchoninic acid procedure using bovine serum
albumin (BSA) as a standard [30].
2.5. Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total mRNA was extracted from liver by the Tri-Reagent method
adapted from the procedure of Chomczynski and Sacchi [31]. Tri-
Reagent was provided by Euromedex (Sou¡elweyersheim, France).
Gene expression was evaluated by semi-quantitative RT-PCR from
1 Wg of total mRNA using Access RT-PCR System from Promega
(Madison, WI, USA). Reverse transcription and cDNA fragment am-
pli¢cation were performed in a Hybaid thermocycler (Omnigene Bio-
products Inc., MA, USA). The sequences of the sense and antisense
primers designed using ‘Primers!’ software and synthesized by MWG-
Biotech AG (Ebersberg, Germany) were for LPL: 5P-CTAAG-
GACCCCTGAAGACACA-3P and 5P-TCTCATACATTCCCGT-
TACCGT-3P, for HL: 5P-GTGAATGTGGGGTTAGTGGAC-3P
and 5P-ACTTCGCAGATTCCTCCAGC-3P, for low-density lipopro-
tein receptor (LDL-R): 5P-CACTTCCGCTGCAAATCATC-3P and
5P-GTGAATGCAGGAGCCATCTG-3P, for diacylglycerol acyltrans-
ferase (DGAT): 5P-GTATCCTGAATTGGTGTGTGGT-3P and 5P-
TAGGGGTCCTTCAAAAACAGAG-3P, and for L-actin: 5P-AAT-
CGTGCGTGACATCAAAG-3P and 5P-GAAAAGAGCCTCAGGG-
CAT-3P. The number of ampli¢cation cycles was determined accord-
ing to a kinetic pro¢le. Control tubes containing no RNA template
were used for contamination checking. RT-PCR products were re-
solved in a 1.7% agarose gel with ethidium bromide and band inten-
sities were measured by densitometric analysis with a Gel Doc 2000
ultraviolet gel documentation system equipped with ‘Quantity One’
software (Bio-Rad S.A., Ivry-sur-Seine, France). For every gene
studied, L-actin was concomitantly ampli¢ed and used for normaliza-
tion.
2.6. Statistics
Di¡erences in mean values between groups were tested by one-way
analysis of variance (ANOVA). Signi¢cant di¡erences between means
were tested by Student’s t-test for an independent variable. When
variances and number of rats were unequal, means were tested by a
Kruskal^Wallis non-parametric test.
3. Results
3.1. Body and lipid parameters
As already reported [5], the body weights of CLA2-fed mice
were signi¢cantly lower than those of controls and CLA1-fed
ones at the end of the experimental period (Table 1). As
regards the relative weights of some organs, there was no
di¡erence between the hearts of mice fed any of the three diets
assayed. CLA2-fed mice were however shown to exhibit a
marked regression of the periepididymal adipose tissue and
a concomitant enlargement of liver. The increase in the total
weight of the liver was in fact associated with a severe fat
accumulation, total lipids containing 90 and 60% of TAG in
the CLA2 and control series, respectively. The above param-
eters appeared to be similar in control and CLA1-fed mice.
Table 1 also shows that plasma TAG concentrations were
reduced after CLA1 feeding and still more after the CLA2
diet (3-fold less) by reference to the control diet. Plasma
apoB content underlined the fact that lipoprotein concentra-
tion was reduced in CLA2-fed mice, but not in CLA1-fed
ones.
3.2. Hepatic VLDL secretion
In order to determine whether the hepatic steatosis of
CLA2-fed mice resulted from a reduced liver lipoprotein out-
Table 1
E¡ects of puri¢ed CLA isomers on body, relative tissue weights and lipid parameters in mice
Control CLA1 CLA2
Body weight (g) 25.7V 0.9 24.7V 0.7 23.3V 0.6*
Liver
Mass (% of body weight) 4.7 V 0.1 4.9V 0.1 7.5 V 0.3***
TAG (mg/g of wet tissue) 8.6 V 1.6 9.4V 2.4 64.9V 6.7***
Periepididymal adipose tissue
Mass (% of body weight) 1.2 V 0.1 1.1V 0.1 0.2 V 0.1***
Plasma
TAG (g/l) 1.04V 0.15 0.64V 0.03* 0.34V 0.03***
ApoB (g/l) 0.081V 0.012 0.103V 0.019 0.038V 0.005**
Data are meansVS.E.M. (n=6). Versus control, *P6 0.05; **P6 0.01; ***P6 0.001.
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put, the secretion rate of VLDL was evaluated in vivo
through the inactivation of LPL [26] : Triton WR-1339 was
reported to inhibit LPL activity and to impair consequently
the VLDL particle clearance. Under these conditions, as
VLDL were no more taken up by cells, their secretion rates
were shown to be about proportional to the increase in plas-
ma VLDL-apoB concentration [32].
The data obtained using this procedure (Fig. 1) show that
the ability of the total liver to secrete VLDL was practically
two times greater in CLA2-fed mice than in controls. How-
ever, as the liver of CLA2-fed mice was itself 1.6 times as
heavy as in controls, the VLDL secretion rate appeared to
be ¢nally about 20% greater per g tissue than in the other
two series. Collectively, these results indicate that the liver
TAG accumulation in CLA2-fed mice could not be attributed
to a decreased VLDL secretion and that the VLDL overpro-
duction from the enlarged liver was however insu⁄cient to
eliminate the £ux of FA entering the whole esteri¢cation
and lipoprotein assembling/secretion pathway.
3.3. Heart and liver lipolytic activities
VLDL oversecretion and lower plasma TAG content
should imply elevated rates of TAG-rich lipoprotein removal
essentially performed through LPL activities. In adipocytes
cultured in the presence of CLA2, the LPL activity was how-
ever demonstrated to be inhibited [7] and we show that the
LPL activity in a energy-demanding organ as the heart was
unaltered in mice fed any of the CLA isomers checked (Fig.
2a). In the liver, the LPL activity was extremely weak and of
about comparable extent in the three series (data not shown).
Meanwhile, the HL activity was found to be insensitive to
either CLA treatment when expressed per mg protein (Fig.
2b), but in CLA2 series the activity was practically of doubled
extent when taking into account the total liver weights by
reference to those of control mice.
3.4. mRNA expression
It has been shown that, in control mice, some genes, such as
FA translocase or adipocyte lipid binding protein, poorly rep-
resented in liver and highly expressed in white adipose tissues,
were markedly induced in the liver after CLA2 treatment [13].
This could also be the case for the LPL gene that was ex-
pressed to a far greater extent in adipose tissues than in the
liver, all the more because LPL might be involved in the
clearance of VLDL at the hepatic level in CLA2-fed mice.
However unexpectedly, no alteration of the liver LPL
mRNA expression was noticeable in either CLA isomer-fed
mice, as compared to controls (Fig. 3). The same possibility
was investigated with HL whose activity was shown above to
be unchanged in the three series. The expression of HL
mRNA was found to be comparatively of the same extent
for all the diets (Fig. 3). However, as speci¢c mRNA levels
were normalized by reference to those of L-actin and not per
total liver, LPL and HL mRNA expressions and activities
were suggested to be greater in the total liver of CLA2-fed
mice.
As compared to the expression of LPL and HL mRNA, the
expression of hepatic LDL-R was demonstrated to be signi¢-
Fig. 1. E¡ect of CLA on liver VLDL-apoB secretion rate. Plasma
ApoB concentrations were determined after intravenous injection of
Triton WR-1339. Data are means (n=8) and T-bars indicate the
S.E.M. All values obtained with CLA2-fed mice were signi¢cantly
di¡erent from those with control mice at P6 0.01.
Fig. 2. E¡ects of triolein concentration on heart and liver lipolytic
activities in control and either CLA-fed mice. LPL and HL activ-
ities were determined using heart and liver homogenate superna-
tants, respectively (see Section 2). Results are means (n=6) and are
expressed as nmol of free FA released from [3H]triolein per mg pro-
tein; T-bars indicate the S.E.M. For all the range of concentrations
tested, no signi¢cant di¡erence in enzyme activity was observed be-
tween control and CLA-fed mice at P6 0.05.
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cantly induced in mice fed either CLA isomer. Concomitantly,
mRNA level of DGAT, that is the last enzyme of the TAG
biosynthesis, was increased in CLA2-fed mice only (Fig. 3).
4. Discussion
The explanations regarding the relations between the setup
of the liver steatosis and blood lipids in mice fed diets con-
taining mixtures of CLA or puri¢ed CLA2 are very scarce and
still confused. For instance, CLA mixtures have been reported
to reduce plasma lipids in rabbits [19], in hamsters [3] and
more particularly the plasma VLDL fraction in rats [20].
Meanwhile, puri¢ed CLA2 was shown to increase plasma
VLDL-TAG in hamsters [22]. In HepG2 cells, CLA2 was
recently demonstrated to suppress TAG secretion and to in-
crease cell TAG contents [17].
4.1. VLDL secretion
In the present study, the underlying issue was addressed for
the ¢rst time in vivo by monitoring the secretion rate of he-
patic VLDL in mice fed the two CLA isomers used in most
studies. The major ¢nding of the investigation was that the
liver VLDL output was increased after CLA2 treatment with-
out concomitant hypertriglyceridaemia, the plasma TAG con-
centrations being even markedly lowered. The estimation of
liver VLDL secretion rate was performed using Triton WR-
1339 which inhibited LPL activities and therefore the blood
clearance of circulating lipoproteins [26] as well as various
TAG-rich particle emulsions [33]. The ¢rst conclusion of the
present work was that the liver steatosis did not result from
an impairment of VLDL assembling/secretion.
4.2. Blood lipid clearance
The lowering of plasma TAG concentrations was unex-
pected in CLA2-fed mice as regards the oversecretion of he-
patic VLDL, which suggested that the VLDL clearance
should be greatly increased in these mice as compared to
controls. LPL activities of extrahepatic organs were factors
capable of improving this clearance. However, this possibility
was unlikely because LPL activity was found to be low in
cultured 3T3-L1 adipocytes treated with CLA2 [7] and owing
to the absence of increased LPL activity in the heart (our
study) that represents a very e⁄cient organ using preferen-
tially FA as oxidative substrates. The non-involvement of or-
gans known to use very actively FA led to suggest that the
liver was itself mostly responsible for the blood lipid clearance
in CLA2-fed mice. However, the activity (see Section 3) and
the level of mRNA expression (Fig. 3) of the hepatic LPL
were found to be very low and unmodi¢ed by any of the
CLA studied. No change was also observed for the activity
and expression of the HL (Figs. 2 and 3) involved in LDL-R-
related protein pathways (for a review see [34]). In CLA2-fed
mice, the 1.6-fold greater liver mass has to be taken into
account, which should increase about proportionally LPL
and HL activities of the whole liver. The pathway mediating
the direct uptake of VLDL and lipoprotein remnants deserves
much more consideration because of the marked elevation of
the LDL-R mRNA expression (Fig. 3). Indeed, the level of
expression of the LDL-R gene has been shown to depend on
the sterol regulatory element binding protein-1a (SREBP-1a)
[35] that was reported to activate genes encoding enzymes of
cholesterol and FA synthesis [35] and to be induced in the
liver of CLA2-fed mice [13]. Taken collectively, the facts in-
dicate that CLA2-fed mice resembled transgenic mice over-
expressing the nuclear form of SREBP-1a since both metabol-
ic situations resulted in enlargement of liver due, at least in
part, to lipid accumulation and marked decrease in periepidi-
dymal adipose tissue mass [35]. The role of the LDL-R in the
VLDL clearance was conversely demonstrated by the disrup-
tion of the LDL-R gene in the transgenic mice, which caused
an increase in plasma cholesterol and TAG concentrations
[36].
4.3. Liver steatosis
Liver fat accumulation and increased blood lipid clearance
likely resulted from the imbalance between the slightly greater
VLDL secretion and the very active internalization of lipo-
protein remnants. Following the lipolysis of remnants in he-
patocytes, FA released must be therefore directed towards the
esteri¢cation pathway. On short term perfusion experiments,
normal livers were shown to be capable of esterifying large
amounts of FA [37], suggesting that the increase in DGAT
mRNA expression in the liver of CLA2-fed mice (Fig. 3)
corresponded to an actual metabolic requirement for meeting
Fig. 3. RT-PCR analysis of gene expression in the liver of control and either CLA-fed mice. Each reaction was performed in triplicate. Results
are expressed as RT-PCR product relative abundance in CLA-fed mice as compared to controls ( = 100) after normalization to the levels of
L-actin mRNA. Data are means (n=3) and T-bars indicate the S.E.M. Versus controls, *P6 0.05; ***P6 0.001.
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the excessive £ux of FA. The inhibition of fat deposit into
peripheral adipose tissues [7] compelled blood lipids to circu-
late more actively from liver and intestine to liver and FA user
organs. The £ux of lipids permanently cleared from blood and
taken up more abundantly by a heavier liver was possibly the
starting point of the observed inductions.
As CLA1 and CLA2 have been reported to be potent li-
gands forperoxisomeproliferator-activated receptorK (PPARK)
[38], the underlying regulations might imply the activation of
PPARK, which was shown to repress apoptosis [39] and there-
fore to favor liver enlargement. The e¡ects of CLA2 were
however preserved in PPARK null mice [40], indicating a com-
plex e¡ect of this CLA isomer on the liver lipid metabolism.
Interestingly, CLA1 was shown to share with CLA2 the plas-
ma lipid-lowering e¡ect (Table 1) and the increase in LDL-R
gene expression (Fig. 3). The absence of lipoatrophy in CLA1-
fed mice strongly suggests that the CLA2 e¡ect primarily
a¡ected adipose tissues with further consequences disturbing
liver lipid metabolism.
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